Price movement over the last 24 hours
Alcon AG vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.6. The key difference: Alcon AG pays a 0.54% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | VIG | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | — |
52-Week High | $92.22 | $239.03 |
52-Week Low | $62.02 | $204.09 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
VIG trades at $238.88, up 0.11% with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. companies with consistent dividend growth, maintaining a low 0.04% expense ratio. Recent news highlights its role in long-term wealth building through dividend compounding, though some analysts favor competitors like DGRO for momentum.
The outlook remains positive for income-focused investors seeking steady dividend growth, but risks include sector concentration in technology and competition from higher-yield alternatives. Wall Street sentiment is generally favorable, with the ETF's strategy appealing for passive income portfolios amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →